Lesson 4: Adis R&D Insight File 107/907

Key Drug Pipeline Databases on Dialog
Lesson 4:
Adis R&D Insight
(File 107/907)

• Objectives
• About Adis R&D Insight
• Why Adis R&D Insight
• The Record
• Exercises
• Summary
• Glossary
• Print Tips
• About the Icons

Links to Other Lessons:

• Lesson 1: Drug Pipeline Directory Basics

• Lesson 2: IMS R&D Focus (File 445/955)

• Lesson 3: Pharmaprojects (File 128/928)

• Lesson 4: Adis R&D Insight (File 107/907)

• Lesson 5: Prous Databases (Files 452,453,458,459)

• Lesson 6: Course Wrap-up

• TOC

Technical Help
with Online Courses

Need Help?
E-mail the

Lesson 4: Adis R&D Insight (File 107/907)

Objectives
After completing this lesson, you will be able to:

Recognize the basic pipeline data, as found in Adis R&D Insight

Use the commercial summary field to help determine when a product will be launched and its potential sales

Find relevant references for your drug by MAPping the Adis R&D Insight reference number to Adis Clinical Trials Insight (File 173)

Determine status of drugs worldwide with the clinical indication included

Sharon,
Glad the information from Pharmaprojects was helpful to you, especially for licensing.

I am going to take a look at File 107, Adis R&D Insight, next. It has some unique company information and comprehensive nomenclature that might interest you.

When I get it, I'll send it over!

Ric

Introduction

We have reviewed the information in IMS R&D Focus (File 445) and Pharmaprojects (File 128). Both databases provided extensive information about the drug vatalanib as it passes through the pipeline.

We will now look at the drug from a different perspective in the database Adis R&D Insight (File 107/907).

Adis R&D Insight comprehensively reports on the latest developments of drugs in active research and development internationally each week. Over 9,000 drugs are included in the database.

Drugs reported in Adis R&D Insight start with the earliest laboratory report and continue through to world market launch. Every scientific or commercial development advancing the drug's progress to market is assessed, evaluated, and reported in Adis R&D Insight.

Go to the next page.

4-1